b2-microglobulin (b2M) functions as a chaperon to maintain structural stability of MHC class I complex that is associated with antigen presentation to cytotoxic (CD8+) T lymphocytes. Cancerous cells in b2M loss-of-function are thought to avoid immune surveillance. As increased level of b2M present in tissue/serum is significantly associated with tumor status in various cancers, b2M may become an important prognostic and survival factor in a range of malignancies. It is believed that b2M acts as hormone-like molecule to trigger a pleiotropic signaling via a ligand-to-receptor binding mechanism. Anti-b2M monoclonal antibodies successfully induce apoptosis in malignant cells, suggesting a surprising therapeutic approach. Of note, b2M is largely localized in the cytoplasm of advanced oral cavity squamous cell carcinoma (OCSCC), in contrast to that in the plasma membrane of normal oral mucosa. This suggests that b2M-derived intracellular signaling might be preceded by its accumulation in the cytoplasm of epithelial cells of tumors. Hence, translocation of b2M from cell surface to cytoplasm in advanced tumors may shed light on the mechanism of b2M-mediated tumorigenesis.
Background b2-Microglobulin (b2M), a structurally light chain of major histocompatibility complex (MHC) class I molecules, is expressed on the surface of all nucleated cells. b2M non-covalently interacts with the heavy chain of MHC class I to function in the presentation of antigenic peptide fragment to cytotoxic (CD8+) T lymphocytes [1] . In the absence of b2M, most MHC class I molecules become less expressed on the surface of cells [2] . Transfection of b2M-deficiency cells with ER-retained b2M restored the function of MHC class I, supporting a role of b2M as chaperone for MHC folding [3] . Nevertheless, b2M is present as a soluble form at low levels in different bodily fluids under physiological conditions. It is increasingly recovered in patients with chronic kidney disease and certain malignancies, including liquid and solid tumors [4, 5] . The elevated level of b2M in body fluid is significantly associated with tumor status and poor prognosis. It is believed that cancer cells frequently downregulate the expression of MHC class I to avoid immune surveillance, allowing gainof-function via the secretion of free b2M. Thus, the free b2M is widely implicated in association with MHC class I-loss tumors.
b2-microglobulin Gain-of-Function in Cancer Cells
There is convincing evidence that b2M acts as a growth-promoting factor and signal molecule in a variety of cancer cells [6] [7] [8] . Overexpression of b2M facilitates the invasion and migration of cancer cells of different origin, supporting the increased levels of b2M positively correlated with advanced-stage tumors. b2M gain-of-function is achieved by regulating the androgen receptor and a cyclic AMP-dependent protein kinase A signaling pathway in prostate cancer. A panel of genes related to cell growth, survival, signaling, and angiogenesis is therefore expressed to trigger tumor progression and cause bone metastasis [6] . Similar results were found in human cancer renal cells, showing that b2M promotes tumor growth via the activation of vascular endothelial growth factor axis [7] . Apart from the finding of b2M as an important prognostic and survival factor in a range of malignancies, it also becomes an attractive therapeutic target. Monoclonal antibodies (mAbs) against b2M have a surprising apoptotic effect on prostate cancer, renal cell carcinoma (RCC), myeloma, and other hematological malignancies [9] [10] [11] [12] . Yang et al. [12] demonstrated that mAbs induce apoptosis in myeloma cells by recruiting MHC class I molecules to lipid rafts and by excluding growth factor receptors. Similarly, Huang et al. [13] revealed that b2M-specific mAb decreases lipid levels in prostate cancer cells to make a link between b2M-mediated intracellular signaling axis and lipid rafts in the cell membrane. This may explain why b2M mAbs-induced apoptosis in cancers is mediated via quite similar signaling pathways -the inhibition of PI3K/Akt, MAPK, and Bcl-2, and the activation of caspases-dependent cascade -supporting the role of b2M as a mitogenic factor. Of note, b2M-specific mAbs have a higher affinity for surface-bound rather than the soluble b2M and display differential sensitivity to malignant cells but not to normal cells, suggesting that the integrity of lipid rafts is an important factor for both apoptotic and survival signaling [9] . Strikingly, Cao et al. [14] reported the effectiveness of IgM antib2M mAbs exhibiting more potent activity than IgG mAbs at inducing tumor cells apoptosis in vitro and in vivo. The enhanced activity of IgM mAbs in tumor cell apoptosis mainly relies on the pentameric structure of the IgM. Apparently, these studies support that b2M-specific mAb is a promising therapeutic agent for the treatment of several types of malignancies, although further work is needed to evaluate the potential cytotoxicity of the antibody targeting approach. Based on a broad range of evidence, it is believed that b2M acts as a hormone-like molecule to trigger pleiotropic signaling via a ligand-to-receptor binding mechanism. Until recently, a noteworthy aspect to b2M in cancer cell signaling was to identify hemochromatosis (HFE) protein with which b2M induces epithelial-mesenchymal transition (EMT) and confers cancer lethality and bone metastasis in a variety of human cancer cells [8] . On the contrary, inhibition of b2M reverses EMT to mesenchymal-to-epithelial transition (MET). This suggests that b2M binds with HFE protein, namely b2M receptor, in association with transferring receptor to modulate iron homeostasis and activate iron-responsive HIF-1a (hypoxia inducible factor-1a) signaling in cancer cells. Because the HIF signaling cascade is activated by the effects of hypoxia, which keeps cells from differentiating, b2M-derived upregulation of HIF-1a mediates EMT and eventually promotes metastasis for cancer progression. Previously, Chen et al. [5] revealed that overexpression of b2M is associated with poor survival in patients with oral cavity squamous cell carcinoma (OCSCC) and contributes to oral cancer cell migration and invasion. The expression level of b2M in the cytoplasm and cytoplasm membrane of OCSCC epithelial cells at various stages was compared with that in normal oral mucosa, clearly showing that b2M localizes largely in the cytoplasm of tumor samples (~90-92% in a total of 256 cases) rather than in the plasma membrane. This suggests that the increased accumulation of b2M in the cytoplasm of OCSCC is significantly correlated with a relatively advanced tumor stage. This highlights the dramatic changes in b2M localization from cytoplasm membrane to cytoplasm between normal and tumor stages of OCSCC. This feature was also reported by Nomura et al. [7] , who found that b2M expression, in a few cases, localized in the cytoplasm of human RCC. Thus, intracellular accumulation of b2M must play a pivotal role in cancer cell signaling and may present a potential target for therapy.
